Latest news with #AnnHynes
Yahoo
04-07-2025
- Business
- Yahoo
Why UnitedHealth Stock Is Sinking Again Today
UnitedHealth Group shares are sliding today following negative industry news from rival insurer Centene. Centene was forced to pull its full-year guidance due to troubling data. The company is facing major issues, including a DOJ fraud investigation and reports of significant misconduct. 10 stocks we like better than UnitedHealth Group › Shares of UnitedHealth Group (NYSE: UNH) are falling today, down 4.5% as of 2:41 p.m. ET. The drop comes as the S&P 500 (SNPINDEX: ^GSPC) gained 0.3% and the Nasdaq Composite (NASDAQINDEX: ^IXIC) gained 0.8%. The troubled health insurance giant is seeing its stock slide after a fellow insurer announced it was pulling its full-year guidance. Centene, a rival insurer, announced late Tuesday that it is pulling its previously set earnings and revenue guidance for 2025. The company said that new data from its Affordable Care Act plans was so poor that it would need to readjust. Centene said that preliminary data indicated it will need to cut its previous 2025 earnings per share (EPS) target of $7.25 by $2.75 per share. Mizuho analyst Ann Hynes told investors this morning she believes it could be cut by as much as half. The massive downward adjustment is the latest in a string of bad news for the insurance industry, leading to stocks slipping across the board. The company is under investigation by the DOJ for fraudulent billing practices in its Medicare division, and a recent investigative report by The Guardian revealed that UnitedHealth has been making secret bonus payments to nursing homes in order to keep ailing residents out of hospitals and save money. The report also claims the company staffed nursing homes with its own medical teams who, at times, interfered in order to keep residents who needed hospital care from receiving it. There are just too many issues facing UnitedHealth at the moment, with no clear picture of an imminent turnaround. This once-seemingly stable investment looks far from it at the moment, and I would stay away from the stock. Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $697,627!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $939,655!* Now, it's worth noting Stock Advisor's total average return is 1,045% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. Why UnitedHealth Stock Is Sinking Again Today was originally published by The Motley Fool Sign in to access your portfolio
Business Insider
18-06-2025
- Business
- Business Insider
Mizuho Securities Reaffirms Their Buy Rating on Surgery Partners (SGRY)
In a report released today, Ann Hynes from Mizuho Securities reiterated a Buy rating on Surgery Partners (SGRY – Research Report), with a price target of $28.00. The company's shares closed today at $20.33. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Hynes covers the Healthcare sector, focusing on stocks such as UnitedHealth, Acadia Healthcare, and Humana. According to TipRanks, Hynes has an average return of 8.9% and a 59.68% success rate on recommended stocks. Currently, the analyst consensus on Surgery Partners is a Moderate Buy with an average price target of $31.22, representing a 53.57% upside. In a report released today, Leerink Partners also reiterated a Buy rating on the stock with a $34.00 price target. The company has a one-year high of $33.97 and a one-year low of $19.50. Currently, Surgery Partners has an average volume of 998.6K.
Yahoo
19-04-2025
- Business
- Yahoo
UnitedHealth was a reliable earnings performer - until its shocking Thursday results
By Sriparna Roy (Reuters) -UnitedHealth has traditionally been a company investors saw as reliable, having not missed earnings estimates since the 2008 global financial crisis. Until Thursday. The country's largest insurer by market value fell far short of expectations with its quarterly earnings, leading to its worst one-day selloff in more than a quarter-century. Its subsequent conference call still left analysts puzzled over the shortfall, even though some praised it for walking analysts through the circumstances that caused the earnings miss. UnitedHealth pulled in revenue of $109.6 billion for the first quarter, about $2 billion shy of expectations, and it also fell short of earnings estimates. The industry bellwether pointed to rising medical costs in its plans for older adults - and what it termed as "unanticipated changes" in its Optum health services subsidiary that was viewed as the growth engine of the conglomerate's business. Several analysts said they were left with a lot of burning questions as the insurer is typically known to be conservative in its forecast and often raises it as the year progresses. "We do not believe the earnings call answered all investors' questions which could indicate a lack of clarity on UNH's part given it is still early in the year," said Mizuho analyst Ann Hynes. At first, investors interpreted the earnings miss as an industry-wide problem, aggressively dumping both UnitedHealth shares and those of its rivals. That approach changed by mid-morning, however, when rival Elevance Health said it still expected quarterly profits to come in as forecast. Investors kept up the selling pressure on UnitedHealth, but the other shares recovered a good chunk of their losses; Elevance, which at one point had been down 5.8%, ended off by just 2.3%. UnitedHealth lost more than 22%, shaving nearly $120 billion off its market value, its biggest one-day selloff since 1998. The company has faced stark challenges over the past year - a cyberattack at its tech unit that affected 200 million Americans and the murder of its insurance unit head, Brian Thompson. His killing outside the company's investor meeting in New York rattled the industry as it triggered an outpouring of anger from Americans frustrated over their dealings with health insurers. In February, the Wall Street Journal reported that the Justice Department was investigating its Medicare billing practices for using unneeded medical codes to increase payments. The health insurer has said it is unaware of a probe. Investors also expressed surprise at the performance of its Optum unit, which includes its pharmacy benefits management division and the prescription drug plans it runs for Medicare. Those plans were affected by changes in 2025 reimbursements. "Optum was kind of always the saving grace, being able to grow through (the challenges)," said Kevin Gade, chief operating officer of investment firm Bahl & Gaynor. "Last year, Optum was always the silver lining that UnitedHealth had versus its peers," he said. Wall Street will be keenly watching details from rivals, especially Humana, another top provider of Medicare Advantage plans whose shares fell 7% on Thursday. "It's the shock of how quickly we saw negative trends develop and then probably added complexity from just the challenging backdrop that the industry has seen for the last year or two," said Leerink Partners analyst Whit Mayo. Sign in to access your portfolio
Reuters
17-04-2025
- Business
- Reuters
UnitedHealth was a reliable earnings performer - until its shocking Thursday results
April 17 (Reuters) - UnitedHealth (UNH.N), opens new tab has traditionally been a company investors saw as reliable, having not missed earnings estimates since the 2008 global financial crisis. Until Thursday. The country's largest insurer by market value fell far short of expectations with its quarterly earnings, leading to its worst one-day selloff in more than a quarter-century. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Its subsequent conference call still left analysts puzzled over the shortfall, even though some praised it for walking analysts through the circumstances that caused the earnings miss. UnitedHealth pulled in revenue of $109.6 billion for the first quarter, about $2 billion shy of expectations, and it also fell short of earnings estimates. The industry bellwether pointed to rising medical costs in its plans for older adults - and what it termed as "unanticipated changes" in its Optum health services subsidiary that was viewed as the growth engine of the conglomerate's business. Several analysts said they were left with a lot of burning questions as the insurer is typically known to be conservative in its forecast and often raises it as the year progresses. "We do not believe the earnings call answered all investors' questions which could indicate a lack of clarity on UNH's part given it is still early in the year," said Mizuho analyst Ann Hynes. At first, investors interpreted the earnings miss as an industry-wide problem, aggressively dumping both UnitedHealth shares and those of its rivals. That approach changed by mid-morning, however, when rival Elevance Health (ELV.N), opens new tab said it still expected quarterly profits to come in as forecast. Investors kept up the selling pressure on UnitedHealth, but the other shares recovered a good chunk of their losses; Elevance, which at one point had been down 5.8%, ended off by just 2.3%. UnitedHealth lost more than 22%, shaving nearly $120 billion off its market value, its biggest one-day selloff since 1998. The company has faced stark challenges over the past year - a cyberattack at its tech unit that affected 200 million Americans and the murder of its insurance unit head, Brian Thompson. His killing outside the company's investor meeting in New York rattled the industry as it triggered an outpouring of anger from Americans frustrated over their dealings with health insurers. In February, the Wall Street Journal reported that the Justice Department was investigating its Medicare billing practices for using unneeded medical codes to increase payments. The health insurer has said it is unaware of a probe. Investors also expressed surprise at the performance of its Optum unit, which includes its pharmacy benefits management division and the prescription drug plans it runs for Medicare. Those plans were affected by changes in 2025 reimbursements. "Optum was kind of always the saving grace, being able to grow through (the challenges)," said Kevin Gade, chief operating officer of investment firm Bahl & Gaynor. "Last year, Optum was always the silver lining that UnitedHealth had versus its peers," he said. Wall Street will be keenly watching details from rivals, especially Humana (HUM.N), opens new tab, another top provider of Medicare Advantage plans whose shares fell 7% on Thursday. "It's the shock of how quickly we saw negative trends develop and then probably added complexity from just the challenging backdrop that the industry has seen for the last year or two," said Leerink Partners analyst Whit Mayo.
Yahoo
17-04-2025
- Business
- Yahoo
UnitedHealth was a reliable earnings performer - until its shocking Thursday results
By Sriparna Roy (Reuters) -UnitedHealth has traditionally been a company investors saw as reliable, having not missed earnings estimates since the 2008 global financial crisis. Until Thursday. The country's largest insurer by market value fell far short of expectations with its quarterly earnings, leading to its worst one-day selloff in more than a quarter-century. Its subsequent conference call still left analysts puzzled over the shortfall, even though some praised it for walking analysts through the circumstances that caused the earnings miss. UnitedHealth pulled in revenue of $109.6 billion for the first quarter, about $2 billion shy of expectations, and it also fell short of earnings estimates. The industry bellwether pointed to rising medical costs in its plans for older adults - and what it termed as "unanticipated changes" in its Optum health services subsidiary that was viewed as the growth engine of the conglomerate's business. Several analysts said they were left with a lot of burning questions as the insurer is typically known to be conservative in its forecast and often raises it as the year progresses. "We do not believe the earnings call answered all investors' questions which could indicate a lack of clarity on UNH's part given it is still early in the year," said Mizuho analyst Ann Hynes. At first, investors interpreted the earnings miss as an industry-wide problem, aggressively dumping both UnitedHealth shares and those of its rivals. That approach changed by mid-morning, however, when rival Elevance Health said it still expected quarterly profits to come in as forecast. Investors kept up the selling pressure on UnitedHealth, but the other shares recovered a good chunk of their losses; Elevance, which at one point had been down 5.8%, ended off by just 2.3%. UnitedHealth lost more than 22%, shaving nearly $120 billion off its market value, its biggest one-day selloff since 1998. The company has faced stark challenges over the past year - a cyberattack at its tech unit that affected 200 million Americans and the murder of its insurance unit head, Brian Thompson. His killing outside the company's investor meeting in New York rattled the industry as it triggered an outpouring of anger from Americans frustrated over their dealings with health insurers. In February, the Wall Street Journal reported that the Justice Department was investigating its Medicare billing practices for using unneeded medical codes to increase payments. The health insurer has said it is unaware of a probe. Investors also expressed surprise at the performance of its Optum unit, which includes its pharmacy benefits management division and the prescription drug plans it runs for Medicare. Those plans were affected by changes in 2025 reimbursements. "Optum was kind of always the saving grace, being able to grow through (the challenges)," said Kevin Gade, chief operating officer of investment firm Bahl & Gaynor. "Last year, Optum was always the silver lining that UnitedHealth had versus its peers," he said. Wall Street will be keenly watching details from rivals, especially Humana, another top provider of Medicare Advantage plans whose shares fell 7% on Thursday. "It's the shock of how quickly we saw negative trends develop and then probably added complexity from just the challenging backdrop that the industry has seen for the last year or two," said Leerink Partners analyst Whit Mayo.
